06/21/22 8:00 AMNasdaq : CLDX clinical trialCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous UrticariaCelldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU). Barzolvolimab is a humanized monoclonal antibodyRHEA-AIneutral
06/16/22 4:01 PMNasdaq : CLDX managementCelldex Announces Two New Appointments to its Board of DirectorsCelldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company’s Board of Directors. “We are thrilled to welcome Cheryl and Garry to our Board of Directors during an important timeRHEA-AIneutral
06/06/22 4:05 PMNasdaq : CLDX conferencesCelldex to Present at the 2022 Jefferies Global Healthcare ConferenceCelldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET. A webcast of theRHEA-AIneutral
05/19/22 9:23 AMNasdaq : CLDX clinical trialCelldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antihistamine refractory chronic spontaneous urticaria (CSU), has been accepted as a late-breakingRHEA-AIneutral
05/05/22 4:01 PMNasdaq : CLDX earningsCelldex Reports First Quarter 2022 Financial Results and Provides Corporate UpdateCelldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “This quarter, we continued to focus on advancing our clinical programs and are on track to reportRHEA-AIneutral
02/28/22 4:01 PMNasdaq : CLDX earningsCelldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateCSU Phase 1b multi-dose data expected in July CDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022 Expanded development of CDX-0159 into Eosinophilic Esophagitis (EoE) Well capitalized with $408.3 million inRHEA-AIneutral
02/22/22 4:01 PMNasdaq : CLDX conferencesearningsCelldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference CallCelldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and corporate highlights. To accessRHEA-AIneutral
02/10/22 4:05 PMNasdaq : CLDX conferencesCelldex to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceCelldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:00 p.m. ET. A webcast ofRHEA-AIneutral
12/08/21 8:01 AMNasdaq : CLDX clinical trialCelldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo NodularisCelldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specifically binds theRHEA-AIneutral
11/12/21 7:00 AMNasdaq : CLDX clinical trialCelldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These dataRHEA-AIvery positive